US7244738B2 - Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists - Google Patents

Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists Download PDF

Info

Publication number
US7244738B2
US7244738B2 US10/884,768 US88476804A US7244738B2 US 7244738 B2 US7244738 B2 US 7244738B2 US 88476804 A US88476804 A US 88476804A US 7244738 B2 US7244738 B2 US 7244738B2
Authority
US
United States
Prior art keywords
methyl
amino
ethyl
quinazolin
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US10/884,768
Other languages
English (en)
Other versions
US20050038016A1 (en
Inventor
Terrence Joseph Connolly
Paul Francis Keitz
Eun Kyung Lee
Jim Li
Francisco Javier Lopez-Tapia
Patrick Finbar McGarry
Chris Richard Melville
Dov Nitzan
Counde O'Yang
Fernando Padilla
Klaus Kurt Weinhardt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Palo Alto LLC
Original Assignee
Roche Palo Alto LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Palo Alto LLC filed Critical Roche Palo Alto LLC
Priority to US10/884,768 priority Critical patent/US7244738B2/en
Assigned to ROCHE PALO ALTO LLC reassignment ROCHE PALO ALTO LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KEITZ, PAUL FRANCIS, LOPEZ-TAPIA, FRANCISCO JAVIER, WEINHARDT, KLAUS KURT, O'YANG, COUNDE, CONNOLLY, TERRENCE JOSEPH, LEE, EUN KYUNG, LI, JIM, MCGARRY, PATRICK FINBAR, MELVILLE, CHRIS RICHARD, NITZAN, DOV, PADILLA, FERNANDO
Publication of US20050038016A1 publication Critical patent/US20050038016A1/en
Priority to US11/821,493 priority patent/US20070265446A1/en
Application granted granted Critical
Publication of US7244738B2 publication Critical patent/US7244738B2/en
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to quinazolinone compounds, more particularly, to 2-arylamine substituted quinazolinone compounds and salts thereof which are useful as alpha-1-adrenergic receptor antagonists.
  • the invention further relates to pharmaceutical compositions containing said compounds, to methods for their use as therapeutic agents, and to processes for making said compounds.
  • Alpha-1-adrenergic receptors are G-protein coupled transmembrane receptors that mediate various actions of the sympathetic nervous system through the binding of the catecholamines, epinephrine, and norepinephrine (NE).
  • NE norepinephrine
  • alpha-1A previously known as alpha-1C
  • alpha-1B previously known as alpha-1D
  • Alpha-1 adrenoceptor antagonists have been shown in numerous clinical studies to be effective in relieving the symptoms associated with benign prostatic hypertrophy, also known as benign prostatic hyperplasia (BPH), an illness typically affecting men over fifty.
  • the symptoms of the condition include, but are not limited to, increased difficulty in urination and sexual dysfunction.
  • Drugs such as prazosin, indoramin, doxazosin and tamsulosin are in common clinical use for BPH, and are effective in reducing both “obstructive” symptoms (e.g. weak stream) and “irritative” symptoms (e.g. nocturia, urinary urge and frequency).
  • cardiovascular effects such as postural hypotension, dizziness, and syncope
  • CNS effects such as aesthenia (tiredness).
  • alpha-1 adrenoceptors Pharmacological studies resulting in the subdivision of alpha-1 adrenoceptors into alpha-1A, alpha-1B, and alpha-1D adrenoceptors have led to the suggestion that development of subtype-selective antagonists may allow for an improved symptomatic treatment of BPH with a lower incidence of dose-limiting side-effects.
  • the instant invention provides arylamine-substituted quinazolinone compounds that are useful as alpha 1 a/b adrenergic receptor antagonists.
  • Certain arylamine quinazoline compounds useful for other purposes are disclosed in Hess et al., Anti-hypertensive 2-Amino-4(3H)-quinazolinones, Medical Research Laboratories , Pfizer & Co. (January 1968); Klopman et al., Molecular Pharmacology, “An Artificial Intelligence Approach to the Study of the Structural Moieties Relevant to Drug - Receptor Interactions in Aldose Reductase Inhibitors,” Vol. 34, No.
  • the present invention is directed to compounds useful as alpha 1A/B adrenergic receptor antagonists having the Formula (I),
  • the compounds of Formula (I) above are surprisingly advantageous in selectively antagonizing the alpha-1A and alpha-1B subtype receptors with selectively lesser activity in antagonizing the alpha-1D adrenergic receptor, particularly compounds where R 5 is other than hydrogen. Accordingly, said compounds of Formula (I) are surprisingly advantageous in methods for treating diseases responsive to alpha-1A and alpha-1B receptor antagonism with reduced side effects.
  • Another aspect of this invention relates to the methods of treating a subject having a disease state that is alleviated by treatment with an alpha 1A/B adrenergic receptor antagonist, which comprises administering to such a subject in need of treatment therefore, a therapeutically effective amount of at least one compound of Formula I.
  • Still another aspect of the invention relates to a process for making the claimed compounds.
  • the inventors herein have discovered a process for making intermediate diones of the formula (II),
  • alkyl means a linear or branched, saturated monovalent hydrocarbon moiety of one to eight carbon atoms (preferably one to six carbon atoms), e.g., methyl, ethyl, n-propyl, 2-propyl, tert-butyl, pentyl, and the like. “Lower alkyl” means an alkyl of one to four carbon atoms. When a subscript is used herein following a carbon atom, the subscript refers to the number of carbon atoms that the named group may contain.
  • C 1-4 alkyl means an alkyl of one to four carbon atoms (i.e., lower alkyl) including methyl, ethyl, propyl, iso-propyl, butyl, and tert-butyl;
  • hydroxy(C 1-4 )alkyl means an alkyl of one to four carbon atoms substituted with a hydroxy group;
  • C 1-4 alkoxyalkyl means an alkyl group substituted with an alkoxy group wherein the alkoxy group has one to four carbon atoms;
  • C 1-4 alkoxy(C 1-4 )alkyl means an alkyl group of one to four carbon atoms substituted with an alkoxy group wherein the alkoxy group has one to four carbon atoms; and so forth.
  • Alkylene means a linear or branched, saturated bivalent hydrocarbon moiety of one to eight (preferably one to six) carbon atoms, e.g., methylene, ethylene, propylene, and the like.
  • alkyl When the term “alkyl” is used as a suffix following another term, as in “phenylalkyl,” or “hydroxyalkyl,” this is intended to refer to an alkyl group, as defined above, being substituted with one or two (preferably one) substituent(s) selected from the other, specifically-named group, also as defined herein.
  • phenylalkyl includes benzyl, phenylethyl, 2-phenylbutyl, and so forth.
  • Hydroxyalkyl includes 2-hydroxyethyl, 1-(hydroxymethyl)-2-methylpropyl, 3,4-dihydroxybutyl, and so forth.
  • Alkoxyalkyl refers to an alkyl group substituted with one to two of OR′, wherein R′ is alkoxy as defined below.
  • substituted alkyl refers to an alkyl group as defined above having one, two, three, or four substituents (preferably one to two substituents), independently selected from the group consisting of halo, haloalkoxy, trifluoromethyl, cyano, nitro, —OR a , —SR a , —S(O)R c , —S(O) 2 R c , —C( ⁇ O)R a , —C( ⁇ O)NR a R b , —C(O) 2 R a , —C(O) 2 NR a R b , —S(O) 2 NR a R b , —NR a R b , —NR a (C ⁇ O)R b , aryl, heteroaryl, cycloalkyl, and/or heterocyclo, wherein R a and R b are independently selected from hydrogen, C 1-6 alkyl, aryl, heteroaryl,
  • a substituted alkyl group is substituted with a cyclic group such as aryl, heteroaryl, cycloalkyl, or heterocyclo
  • said cyclic group in turn may be substituted with one, two or three groups selected from alkyl, halo, haloalkyl, OR e , haloalkoxy, cyano, —NR e R f , —SO 2 (alkyl), —CO 2 R c , —C( ⁇ O)R e , and/or —NR e C( ⁇ O)R f , and/or a C 1-6 alkyl substituted with one to two of halo, OR e , haloalkoxy, cyano, —NR e R f , —SO 2 (alkyl), —CO 2 R e , —C( ⁇ O)R e , and/or —NR e C( ⁇ O)R f , wherein R e ,
  • substituted alkylene means an alkylene group as defined above wherein one, two or three carbon atoms of the alkylene straight or branched chain is substituted with a group selected from those recited above for substituted alkyl groups.
  • substituted lower alkyl means an alkyl of one to four carbon atoms having one, two, or three substituents selected from those recited above for substituted alkyl.
  • alkenyl means a linear or branched, unsaturated monovalent hydrocarbon moiety of two to eight carbon atoms (preferably two to six carbon atoms), having at least one double bond, e.g., ethenyl, propenyl, butenyl, and the like.
  • “Lower alkenyl” means an alkenyl of two to four carbon atoms.
  • Alkenylene means a linear or branched, unsaturated bivalent hydrocarbon moiety of two to eight (preferably two to six) carbon atoms, having at least one double bond, e.g., ethenylene, propenylene, and the like.
  • substituted alkenyl refers to an alkenyl group as defined above having one, two, or three substituents, as valence permits (preferably one substituent), independently selected from the group of substituents recited above for “substituted alkyl.”
  • a “substituted alkenylene” has one, two, or three substituents, as valence permits (preferably one substituent), independently selected from the group of substituents recited for “substituted alkyl.”
  • Alkoxy refers to the group OR, wherein R is alkyl or substituted alkyl.
  • a “lower alkoxy” is a group —OR′ wherein R′ is C 1-4 alkyl.
  • aryloxy refers to the group —O—R, wherein R is aryl
  • heteroaryloxy refers to the group —O—R′, wherein R′ is heteroaryl
  • arylalkyloxy refers to the group —O—R′′, wherein R′′ is arylalkyl such as benzyl.
  • a “substituted aryloxy” means the group —O—R, wherein R is substituted aryl
  • a “substituted heteroaryloxy” means the group —O—R′, wherein R′ is substituted heteroaryl
  • amino refers to the group NH 2 .
  • an aminoalkyl refers to an alkyl group having an amino substituent, e.g., —CH 2 —NH 2 , —CH 2 —CH 2 —NH 2 , —CH 2 —CH(NH 2 )—CH 3 , and so forth.
  • Alkylamino refers to monoalkylamino groups having the formula —NHR, as well as dialkylamino groups having the formula —NRR′, wherein each R and R′ are selected from alkyl and substituted alkyl groups as defined above.
  • alkylaminoalkyl refers to an alkyl group substituted by one to two of —NHR and/or —NRR′, wherein each R and R′ is as defined above.
  • a “lower alkylamino” refers to a group —NHR′ or —NR′R′, wherein each R′ is C 1-4 alkyl.
  • Aminoalkoxy means a group —O—R—NHR′ or —O—R—NR′R′′ wherein R is alkylene as defined herein and R′ and R′′ each independently are alkyl as defined herein.
  • alkoxyalkylamino refers to the group —NR f R g , wherein R f is hydrogen, alkyl, or alkoxyalkyl, and R g is an alkoxyalkyl (i.e., an alkyl group substituted with an alkoxy).
  • Alkoxyalkylaminoalkyl refers to an alkyl group as defined above that is substituted with an alkoxyalkylamino group as defined above.
  • a “hydroxyalkylamino” refers to the group —NR h R i , wherein R h is hydrogen, alkyl, or hydroxyalkyl, and R i is hydroxyalkyl (i.e., an alkyl group substituted with hydroxy).
  • Haldroxyalkylaminoalkyl refers to refers to an alkyl group as defined above that is substituted with a hydroxyalkylamino group as defined above.
  • Aminoalkoxy means a group —O—R—NHR′ or —O—R—NR′R′′ wherein R is alkylene as defined above and R′ and R′′ each independently are alkyl as defined above.
  • alkylsulfonyl refers to the group —SO 2 R, wherein R′ is alkyl or substituted alkyl
  • alkylsulfinyl refers to the group —S( ⁇ O)R, wherein R is alkyl or substituted alkyl.
  • methylsulfonyl refers to —SO 2 CH 3
  • methylsulfinyl refers to the group —S( ⁇ O)CH 3 .
  • Alkylsulfonylalkyl means an alkyl group as defined above substituted with an alkylsulfonyl group as defined herein.
  • Alkylsulfonylaminoalkyl means a group —R—NR′—SO 2 —R′′ wherein R is alkylene as defined above and R′ and R′ each independently are alkyl as defined herein.
  • each R is independently hydrogen or alkyl as defined herein.
  • Alkoxyalkyl means a group —R—OR′ wherein R is alkylene as defined above and R′ is alkyl as defined herein.
  • Alkoxyalkoxy means a group —O—R—OR′ wherein R is alkylene as defined above and R′ is alkyl as defined herein.
  • carboxy refers to the group CO 2 H.
  • a carboxyalkyl is an alkyl group as defined above having at least one substituent that is —CO 2 H.
  • alkoxycarbonyl refers to the group —C( ⁇ O)R′, wherein R′ is alkoxy as defined above, i.e., alkoxycarbonyl is CO 2 R, wherein R′ is alkyl or substituted alkyl, as defined above.
  • a “lower alkoxycarbonyl” refers to the group CO 2 R′, wherein R′ is lower alkyl.
  • an alkylalkoxycarbonyl is an alkyl group as defined above having at least one substituent that is —CO 2 R, wherein R′ is alkyl or substituted alkyl, as defined above.
  • Alkoxyalkylaminocarbonyl means a group —(C ⁇ O)—NR—R′—OR′′ wherein R is hydrogen or alkyl as defined herein, R′ is alkylene as defined herein, and R′′ is alkyl as defined herein.
  • Haldoxyalkylaminocarbonyl means a group —(C ⁇ O)—NR—R′—OH′′ wherein R is hydrogen or alkyl as defined herein and R′ is alkylene as defined herein.
  • Aminoalkylaminocarbonyl means a group —(C ⁇ O)—NR—R′—NR′′R′′ wherein R is hydrogen or alkyl as defined herein, R′ is alkylene as defined herein, and each R′′ independently is hydrogen or alkyl as defined herein.
  • Heterocyclylalkylaminocarbonyl means a group —(C ⁇ O)—NR—R′—R′′ wherein R is hydrogen or alkyl as defined herein, R′ is alkylene as defined herein, and R′′ is heterocyclyl as defined herein.
  • alkylamidyl or alkylamide refers to the group —NH(C ⁇ O)R or —NR′(C ⁇ O)R, wherein R is alkyl or substituted alkyl, and R′ is lower alkyl.
  • a lower alkylamidyl is a group —NH(C ⁇ O)R′ or —NR′(C ⁇ O)R′, where R′ is lower alkyl.
  • aryl refers to a monovalent, monocyclic or bicyclic moiety in which at least one of the rings is an aromatic, carbocyclic moeity.
  • aryl includes phenyl, 1-napthyl, and 2-napthyl.
  • aryl also includes phenyl rings having fused thereto a second non-aromatic carbocyclic ring, or second fused heteroaryl or heterocyclic ring (thus, the term aryl includes groups such as benzothienyl, benzopyrazolyl, benzopiperadinyl, benzocyclohexyl, and the like), with the understanding, however, that in the case of bicyclic aryl groups, the point of attachment will be to the phenyl ring.
  • a “substituted aryl” is an aryl group as defined above having one to four (preferably one to two) substituents independently selected from the group consisting of halo, haloalkyl, haloalkoxy, cyano, hydroxy, alkoxy, alkyl, substituted alkyl, —SO 2 R r , —NR p SO 2 R r , —NR p C( ⁇ O)R q , —NR p R q , —C( ⁇ O)NR p R q , —SO 2 NR p R q , —NR p C( ⁇ NR s )R q , —N ⁇ C(R t )R u , —SO 2 N ⁇ C(R t )R u , —C( ⁇ O)R p , —CO 2 R p , and —OR p , heterocyclo, heteroaryl, phenyl and cycloalkyl
  • Carbocyclic means a cyclic moiety in which all ring atoms are carbon atoms, including saturated, partially unsaturated, and unsaturated rings.
  • “Carbamylalkyl” means a group of the formula:
  • each R is independently hydrogen or alkyl.
  • cycloalkyl refers to saturated or partially unsaturated, monovalent, monocyclic carbocyclic moieties of three to seven ring carbon atoms and further includes such rings having a carbon-carbon bridge of one, two, or three bridgehead carbon atoms, and/or having a second ring fused thereto, with the understanding that the point of attachment will be to the non-aromatic carbocyclic ring moiety.
  • cycloalkyl includes such rings as cyclopropyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, and the like.
  • one or two carbon atoms of a cycloalkyl group may optionally contain a carbonyl oxygen group, e.g., one or two atoms in the ring may be a moiety of the formula —C( ⁇ O)—.
  • a “substituted cycloalkyl” is a cycloalkyl group as defined above having one to four (preferably one to two) substituents independently selected from the group consisting of substituents recited above for substituted aryl.
  • Formamidinyl means a group of the formula:
  • R is hydrogen or alkyl as defined herein.
  • N,N-dimethyl formamidine or “N,N-dimethyl formamidinyl” refers to the above group wherein R is methyl.
  • halo when referring to a substituent means fluoro, chloro, bromo, or iodo (preferably fluoro or chloro).
  • haloalkyl means alkyl substituted with one or more same or different halo atoms, e.g., —CH 2 Cl, —CF 3 , —CH 2 CF 3 , —CH 2 CCl 3 , and the like, and further includes those alkyl groups such as perfluoroalkyl in which all alkyl hydrogen atoms are replaced by fluorine atoms.
  • haloalkoxy means a haloalkyl group as defined above linked through an oxygen atom, e.g., it includes —O—CH 2 Cl, —O—CF 3 , —O—CH 2 CF 3 , —O—CH 2 CCl 3 , and the like.
  • Haloalkylamino means a group —NH—R′′ or —NR′—R′′ wherein R′ is alkyl or haloalkyl as defined herein and R′′ is haloalkyl as defined herein.
  • Haloalkylaminoalkyl means a group —R—NH—R′′ or —NR′—R′′ wherein R is alkylene as defined herein, R′ is alkyl or haloalkyl as defined herein and R′′ is haloalkyl as defined herein.
  • Haldroxyalkyl means a group —R—OH wherein R is alkylene as defined herein.
  • Haldroxyalkoxy means a group —O—R—OH wherein R is alkylene as defined herein.
  • Heterocyclo refers to a saturated or partially-unsaturated non-aromatic monocyclic or bicyclic moiety in which one or two ring atoms are heteroatoms selected from N, O, or S(O) x (where x is an integer from 0 to 2), the remaining ring atoms being carbon atoms, and additionally, one or two carbon atoms may optionally contain a carbonyl oxygen group, e.g., one or two atoms in the ring may be a moiety of the formula —C( ⁇ O)—.
  • heterocyclo includes rings such as tetrahydropyranyl, tetrahydrofuryl, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, and the like, as well as such rings having a carbonyl oxygen atom in the ring.
  • rings such as tetrahydropyranyl, tetrahydrofuryl, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, and the like, as well as such rings having a carbonyl oxygen atom in the ring.
  • one of the two rings may be a carbocyclic ring with the understanding that in such cases the point of attachment will be to the heterocyclic ring.
  • Heterocyclylalkylamino means a group —NR—R′—R′′ wherein R is hydrogen or alkyl as defined herein, R′ is alkylene as defined herein, and R′′ is heterocyclyl as defined herein.
  • Imidazolinyl groups as defined herein may be optionally substituted with alkyl.
  • Imidazolinylalkyl means a group —R—R′ wherein R is alkylene as defined herein and R′ is imidazolinyl as defined herein.
  • substituted heterocyclo or “substituted heterocycle” refers to a heterocyclo group as defined above having one to four substituents (preferably one to two substituents) selected from the group of substituents recited above for substituted aryl.
  • heterocyclylene means a bivalent heterocyclyl group as defined above, i.e., a heterocyclyl attached to two other groups (e.g., —NR 10 and Ar in compounds of Formula I).
  • a “heterocyclylC 1-4 alkylene” means a group X—R, wherein X is a heterocyclyl as defined above and R is a C 1-4 alkylene as defined above.
  • An optionally-substituted “heterocyclylC 1-4 alkylene” means a group X—R, wherein X is an optionally-substituted heterocyclyl as defined herein and R is an optionally substituted C 1-4 alkylene as defined herein.
  • Heteroaryl means a monovalent, monocyclic aromatic moiety of 5 to 6 ring atoms containing one, two, three, or four ring heteroatoms, each independently selected from N, O, or S, the remaining ring atoms being carbon, and it also includes such rings having a second ring fused thereto of five to six ring atoms, wherein the second fused ring may be aromatic or nonaromatic and may be carbocyclic, heterocyclic, or a heteroaryl ring, with the understanding, however, that in such cases the point of attachment will be to an aromatic ring containing at least one heteroatom.
  • heteroaryl includes, but is not limited to, pyridyl, furyl, thiophenyl, thiazolyl, isothiazolyl, triazolyl, imidazolyl, isoxazolyl, pyrrolyl, pyrazolyl, pyrimidinyl, benzofuryl, isobenzofuryl, benzothiazolyl, benzoisothiazolyl, benzotriazolyl, indolyl, isoindolyl, benzoxazolyl, quinolyl, isoquinolyl, benzimidazolyl, benzisoxazolyl, benzothiophenyl, dibenzofuran, and benzodiazepin-2-one-5-yl, and derivatives thereof.
  • a “substituted heteroaryl” is a heteroaryl ring as defined above having one to four (preferably one or two) substituents selected from the group of substituents recited above for substituted aryl.
  • Optionally substituted pyrrolidinyl means a group:
  • E is —CH 2 — or —(C ⁇ O)— and R is alkyl, alkoxy or hydroxy.
  • Optionally substituted pyrrolidinylalkyl means a group —R—R′ wherein R is alkylene as defined herein and R′ is imidazolinyl as defined herein.
  • “Ureidylalkyl” means a group:
  • each R is independently hydrogen or methyl.
  • Leaving group has the meaning conventionally associated with it in synthetic organic chemistry, i.e., an atom or a group capable of being displaced by a nucleophile and includes halo (such as chloro, bromo, and iodo), alkanesulfonyloxy, arenesulfonyloxy, alkylcarbonyloxy (e.g., acetoxy), arylcarbonyloxy, mesyloxy, tosyloxy, trifluoromethanesulfonyloxy, aryloxy (e.g., 2,4-dinitrophenoxy), methoxy, N,O-dimethylhydroxylamino, and the like.
  • halo such as chloro, bromo, and iodo
  • alkanesulfonyloxy arenesulfonyloxy
  • alkylcarbonyloxy e.g., acetoxy
  • arylcarbonyloxy mesyloxy, tosyloxy
  • Optional or “optionally” means that the subsequently described event may but need not occur, and it includes instances where the event occurs and instances in which it does not.
  • optionally-substituted cycloalkyl refers to both cycloalkyl groups and substituted cycloalkyl groups, as defined above.
  • optionally-substituted precedes a number of different types of rings in one line or string, e.g., as in “optionally-substituted cycloalkyl or heterocyclo”, or “optionally-substituted carbocyclic or heterocyclic ring,” or “optionally-substituted aryl, heteroaryl, cycloalkyl, or heterocyclo,” it is intended that the term “optionally-substituted” modifies each of the rings identified in the line or string.
  • an “optionally-substituted imidazolyl” may be an unsubstituted imidazolyl or an imidazolyl group having one, two, or three substituents selected from those recited above for substituted heteroaryl groups.
  • An optionally-substituted phenyl or benzyl ring will include an unsubstituted phenyl or benzyl group, and a phenyl or benzyl group having substituents selected from those recited above for substituted aryl groups.
  • heterocyclo or cycloalkyl group such as cyclopentyl, pyrrolidinyl, pyrrolinyl, and imidazolinyl
  • such reference is intended to include such rings wherein optionally one to two carbon atoms of the named ring contain a carbonyl oxygen group, e.g., one or two atoms in the ring may be a moiety of the formula —C( ⁇ O)—, as set forth above in the definition of cycloalkyl and heterocyclo.
  • An optionally-substituted benzyl group means a benzyl group wherein the phenyl portion of the group is unsubstituted or substituted as defined above in the definition for substituted aryl.
  • a benzyl group having a para substituent selected from hydroxy and CO 2 H means a group having the formula
  • R is hydroxy or CO 2 H
  • benzyl having a hydroxy meta substituent means a group having the formula
  • “Pharmaceutically acceptable excipient” means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable. The term includes excipients that are acceptable for veterinary use as well as human pharmaceutical use. A “pharmaceutically acceptable excipient” as used in the specification and claims includes both one and more than one such excipient.
  • “Pharmaceutically acceptable salt” of a compound means a salt that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and which possesses the desired pharmacological activity of the parent compound.
  • Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, trifluoroacetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid,
  • prodrug and “prodrug” are used interchangeably herein and refer to any compound which releases an active parent drug according to Formula I in vivo when such prodrug is administered to a mammalian subject.
  • Prodrugs of a compound of Formula I are prepared by modifying one or more functional group(s) present in the compound of Formula I in such a way that the modification(s) may be cleaved in vivo to release the parent compound.
  • Prodrugs include compounds of Formula I wherein a hydroxy, amino, or sulfhydryl group in a compound of Formula I is bonded to any group that may be cleaved in vivo to regenerate the free hydroxyl, amino, or sulfhydryl group, respectively.
  • prodrugs include, but are not limited to, esters (e.g. acetate, dialkylaminoacetates, formates, phosphates, sulfates and benzoate derivatives) and carbamates of hydroxy functional groups (e.g. N,N-dimethylcarbonyl), esters of carboxyl functional groups (e.g. ethyl esters, morpholinoethanol esters), N-acyl derivatives (e.g. N-acetyl), N-Mannich bases, Schiff bases and enaminones of amino functional groups, oximes, acetals, ketals, and enol esters of ketones and aldehyde functional groups in compounds of Formula I, and the like.
  • esters e.g. acetate, dialkylaminoacetates, formates, phosphates, sulfates and benzoate derivatives
  • carbamates of hydroxy functional groups e.g. N,N-dimethylcarbonyl
  • the prodrug can be metabolized before absorption, during absorption, after absorption, or at a specific site. Although metabolism occurs for many compounds primarily in the liver, almost all other tissues and organs, especially the lung, are able to carry out varying degrees of metabolism. Prodrug forms of compounds may be utilized, for example, to improve bioavailability, improve subject acceptability such as by masking or reducing unpleasant characteristics such as bitter taste or gastrointestinal irritability, alter solubility such as for intravenous use, provide for prolonged or sustained release or delivery, improve ease of formulation, or provide site-specific delivery of the compound. Reference to a compound herein includes prodrug forms of a compound. Prodrugs are described in The Organic Chemistry of Drug Design and Drug Action , by Richard B.
  • Solvate means solvent addition form that contains either stoichiometric or non-stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water the solvate formed is a hydrate, when the solvent is alcohol, the solvate formed is an alcoholate.
  • Protecting group refers to an atom or group of atoms that is attached to a reactive group in a molecule and masks, reduces, or prevents the reactivity of the group to which it is attached.
  • Representative amino protecting groups include formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (CBZ), tert-butoxycarbonyl (Boc), trimethyl silyl (TMS), 2-trimethylsilyl-ethanesulfonyl (SES), trityl and substituted trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl (FMOC), nitro-veratryloxycarbonyl (NVOC), and the like.
  • hydroxy protecting groups include those where the hydroxy group is either acylated or alkylated such as with benzyl or lower alkyl and trityl ethers as well as alkyl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers, and allyl ethers.
  • isomers Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers.” Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”. Stereoisomers that are not mirror images of one another are termed “diastereomers,” and those that are non-superimposable mirror images of each other are termed “enantiomers”. When a compound has an asymmetric center, for example, if a carbon atom is bonded to four different groups, a pair of enantiomers is possible.
  • An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the (R) and (S) sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or ( ⁇ )-isomers respectively).
  • a chiral compound can exist as either an individual enantiomer or as a mixture thereof. A mixture containing different enantiomers is called a “racemic mixture”.
  • the compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)-stereoisomers or as mixtures thereof. Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures (racemic or otherwise) thereof.
  • the methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see March, Advanced Organic Chemistry , Chap. 4, 4th edition, John Wiley and Sons, New York [1992]).
  • Tautomers refers to compounds whose structures differ markedly in arrangement of atoms, but which exist in easy and rapid equilibrium. It is to be understood that compounds of Formula I may be depicted as different tautomers. For example, compounds of Formula I wherein Z is —C(O)—, may be depicted in the following tautomer forms:
  • Compounds of Formula I may also contain other groups that exist in tautomeric equilibrium.
  • some of the compounds contain an imidazolin-2-yl amino group which may be in equilibrium with an imidazolin-2-ylidenamino group:
  • Treating” or “treatment” of a disease includes: (1) preventing the disease, i.e., causing the clinical symptoms of the disease not to develop in a mammal that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease; (2) inhibiting the progression of the disease, i.e., arresting or reducing the development of the disease or its symptoms; and (3) relieving the disease, i.e., causing regression of the disease or its symptoms.
  • a therapeutically effective amount means the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to effect a treatment for the disease.
  • the “therapeutically effective amount” will vary depending on such factors as the compound being administered, the type of disease being treated, the progression or severity of the disease state, and the age, weight, and general health of the mammal being treated.
  • “Patient” means mammals and non-mammals. Mammals means any member of the mammalia class including, but not limited to, humans, non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, and swine; domestic animals such as rabbits, dogs, and cats; and laboratory animals such as rats, mice, and guinea pigs. Examples of non-mammals include, but are not limited to, birds, reptiles, and the like.
  • “Pharmacological effect” as used herein encompasses effects produced in the patient that achieve the intended purpose of a therapy.
  • a pharmacological effect means that primary indications of the patient being treated are prevented, alleviated, or reduced.
  • a pharmacological effect would be one that results in the prevention, alleviation or reduction of primary indications in a treated patient.
  • a pharmacological effect means that disorders or symptoms of the primary indications of the patient being treated are prevented, alleviated, or reduced.
  • Disease state means any disease, condition, symptom, or indication.
  • disorders of the urinary tract refer to pathologic changes in the urinary tract and symptoms thereof.
  • disorders of the urinary tract include overactive bladder (also known as detrusor hyperactivity), outlet obstruction, outlet insufficiency, pelvic hypersensitivity, incontinence, benign prostatic hypertrophy or hyperplasia (BPH), prostatitis, detrusor hyperreflexia, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urge incontinence, urethritis, prostatodynia, cystitis, and idiophatic bladder hypersensitivity.
  • overactive bladder also known as detrusor hyperactivity
  • outlet obstruction also known as detrusor hyperactivity
  • outlet insufficiency outlet obstruction
  • pelvic hypersensitivity incontinence
  • prostatitis detrusor hyperreflexia
  • urinary frequency nocturia
  • urinary urgency pelvic hypersensitivity
  • urge incontinence urethritis
  • “Overactive bladder” or “Detrusor hyperactivity” includes, but is not limited to, changes symptomatically manifested as urgency, frequency, reduced bladder capacity, and incontinence episodes; changes urodynamically manifested as changes in bladder capacity, micturition threshold, unstable bladder contractions, and sphincteric spasticity; and symptoms usually manifested in detrusor hyperreflexia (neurogenic bladder), in conditions such as outlet obstruction, outlet insufficency, pelvic hypersensitivity, or in idiopathic conditions such as detrusor instability.
  • Outlet obstruction includes, but is not limited to, benign prostatic hypertrophy or benign prostatic hyperplasia (BPH), urethral stricture disease, tumors and the like. It is usually symptomatically manifested as obstructive (low flow rates, difficulty in initiating urination, and the like), or irritative (urgency, suprapubic pain, and the like).
  • BPH benign prostatic hypertrophy
  • urethral stricture disease tumors and the like. It is usually symptomatically manifested as obstructive (low flow rates, difficulty in initiating urination, and the like), or irritative (urgency, suprapubic pain, and the like).
  • Outlet insufficiency includes, but is not limited to, urethral hypermobility, intrinsic sphincteric deficiency, or mixed incontinence. It is usually symptomatically manifested as stress incontinence.
  • Pelvic Hypersensitivity includes but is not limited to, pelvic pain, interstitial (cell) cystitis, prostadynia, prostatitis, vulvadynia, urethritis, orchidalgia, and the like. It is symptomatically manifested as pain, inflammation or discomfort referred to the pelvic region, and usually includes symptoms of overactive bladder.
  • “Sexual dysfunction” means the inability to achieve a normal sexual response and includes such conditions in males and females. Thus, it includes male erectile dysfunction (MED) and female sexual dysfunction (FSD).
  • MED male erectile dysfunction
  • FSD female sexual dysfunction
  • CNS disease states associated with the Central Nervous System mean neurological and/or psychiatric changes in the CNS, e.g., brain and spinal cord, which manifest in a variety of symptoms.
  • CNS disease states include, but are not limited to, migraine headache; cerebrovascular deficiency; psychoses including paranoia, schizophrenia, attention deficiency, and autism; obsessive/compulsive disorders including anorexia and bulimia; posttraumatic stress disorders, sleep disorders, convulsive disorders including epilepsy and withdrawal from addictive substances; cognitive diseases including Parkinson's disease and dementia; and anxiety/depression disorders such as anticipatory anxiety (e.g., prior to surgery, dental work and the like), depression, mania, seasonal affective disorder (SAD), and convulsions and anxiety caused by withdrawal from addictive substances such as opiates, benzodiazepines, nicotine, alcohol, cocaine, and other substances of abuse; and improper thermoregulation.
  • SAD seasonal affective disorder
  • the compounds of this invention demonstrate selectivity for the alpha-1A/B subtype over the alpha-1D subtype.
  • the compounds of this invention may reduce both obstructive and irritative symptoms in patients with BPH.
  • the attenuated antagonism of alpha 1D-adrenoceptor is expected to lead to reduced or fewer side effects than those associated with the use of non-subtype-selective agents.
  • the compounds of the invention are of the Formula (I)
  • Preferred compounds are those compounds having the Formula (Ia),
  • R 5 is not hydrogen. Even more preferred are compounds where R 5 is selected from halogen, hydroxy, cyano, —R 6 , and —OR 6 , wherein R 6 is selected from C 1-4 alkyl, aminoalkyl, C 1-4 alkylamino(C 1-4 alkyl), hydroxyalkyl, alkoxyalkyl, phenoxyalkyl, benzyloxyalkyl, cycloalkylalkyl, phenyl, benzyl, and cycloalkyl, wherein each of said phenyl, benzyl, and cycloalkyl groups is optionally substituted with one to two of lower alkyl, substituted lower alkyl, cyano, and/or halogen.
  • R 5 is selected from methyl, ethyl, n-propyl, isopropyl, cyano, halogen, methoxy, and ethoxy. Most preferred are compounds wherein R 5 is methyl or methoxy.
  • R and R′ are both CH 3 .
  • R 10 is selected from hydrogen, alkyl, amino(C 1-6 )alkyl, (C 1-6 )alkylamino(C 1-6 )alkyl, hydroxy(C 1-6 )alkyl, and an optionally-substituted five or six membered heterocyclo or C 3-7 cycloalkyl. More preferred are compounds wherein R 10 is selected from hydrogen, lower alkyl, amino(C 1-4 )alkyl, (C 1-4 )alkylamino(C 1-2 )alkyl, hydroxy(C 1-4 )alkyl, and piperidinyl optionally-substituted with lower alkyl or benzyl.
  • R 10 is selected from hydrogen, lower alkyl, hydroxymethyl, hydroxyethyl, —C 1-4 alkylene-NH 2 , —C 1-4 alkylene-NH(CH 3 ), and/or —C 1-4 alkylene-N(CH 3 ) 2 , and most preferred are compounds wherein R 10 is methyl or ethyl.
  • Ar is is phenyl substituted with a group selected from:
  • R a , R b , and R d are independently hydrogen, C 1-6 alkyl, aryl, heteroaryl, cycloalkyl, or heterocyclo, and R c is alkyl, aryl, heteroaryl, cycloalkyl, or heterocyclo, and each of R a , R b , R c , and R d in turn is optionally substituted with one, two, or three of alkyl, halo, haloalkyl, OR e , haloalkoxy, cyano, —NR e R f , —SO 2 (alkyl), —CO 2 R e , —C( ⁇ O)R e , and
  • each R j , R p , R q , and R r is independently hydrogen, alkyl, substituted alkyl, cycloalkyl, heterocyclo, aryl, or heteroaryl, except R r is not hydrogen, or alternatively, R p and R q when attached to the same nitrogen atom may be taken together to form a heterocyclo or heteroaryl.
  • R j , R p , R q , and R r are and/or forms a ring
  • said cyclic groups in turn are optionally substituted with one to three substituents selected from the group consisting of alkyl, substituted alkyl, halogen, haloalkoxy, trifluoromethyl, cyano, nitro, —OR a , —SR a , —S(O)R c , —S(O) 2 R c , —C( ⁇ O)R a , —C( ⁇ O)NR a R b , —C(O) 2 R a , —C(O) 2 NR a R b , —S(O) 2 NR a R b , —NR a R b , and —NR a (C ⁇ O)R b .
  • R 7 may be selected from hydroxyalkoxy, optionally substituted pyrrolodinyl, alkylaminoalkyl, alkylsulfonylaminoalkyl, haloalkylaminoalkyl, alkoxyalkylaminoalkyl, hydroxyalkylaminoalkyl, aminoalkoxy, aminoalkyl, ureidylalkyl, carbamylalkyl, acetamidinyl, formamidinyl, optionally substituted imidazolinyl, optionally substituted pyrrolodinylmethyl, optionally substituted imidazolinylmethl, alkoxyalkylaminocarbonyl, hydroxyalkylaminocarbonyl, aminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, and heterocyclylalkylamino.
  • R 7 may be selected from methyl-(3,3,3-trifluoro-propyl)-amino-methyl-, 2-hydroxy-3-methoxy-propoxy-, methoxy-, 3-hydroxy-2-hydroxymethyl-propoxy-, 1-(dimethylamino-carbonyl-methylamino)-ethyl-, 1-[(methoxycarbonyl)-methylamino]-ethyl-, 3-hydroxy-2-hydroxymethyl-propoxy-, 2,3-dihydroxypropoxy-, (S)-4-methoxy-2-oxo-pyrrolidin-1-yl-, 2-methoxyethoxy-carbonylaminomethyl-, methanesulfonyl-N-methylamino-methyl-, 4,5-dihydro-oxazol-2-yl-, 2-oxo-pyrrolidin-1-yl-, 2-[(2-hydroxy-ethyl)-methyl-amino]-ethoxy-, 3-hydroxy-2-oxo-pyr
  • R 7 may be selected from:
  • R 30 and R 31 each independently is selected from hydrogen, methyl, ethyl, methoxyethyl and hydroxyethyl, and R 32 is hydrogen, methyl or ethyl.
  • R 7 may be selected from:
  • R 8 may be selected from hydroxyalkoxy, optionally substituted pyrrolodinyl, alkylaminoalkyl, alkylsulfonylaminoalkyl, haloalkylaminoalkyl, alkoxyalkylaminoalkyl, hydroxyalkylaminoalkyl, aminoalkoxy, aminoalkyl, ureidylalkyl, carbamylalkyl, acetamidinyl, formamidinyl, optionally substituted imidazolinyl, optionally substituted pyrrolodinylmethyl, optionally substituted imidazolinylmethl, alkoxyalkylaminocarbonyl, hydroxyalkylaminocarbonyl, aminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, and heterocyclylalkylamino.
  • R 8 may be selected from methyl-(3,3,3-trifluoro-propyl)-amino-methyl-, 2-hydroxy-3-methoxy-propoxy-, methoxy-, 3-hydroxy-2-hydroxymethyl-propoxy-, 1-(dimethylamino-carbonyl-methylamino)-ethyl-, 1-[(methoxycarbonyl)-methylamino]-ethyl-, 3-hydroxy-2-hydroxymethyl-propoxy-, 2,3-dihydroxypropoxy-, (S)-4-methoxy-2-oxo-pyrrolidin-1-yl-, 2-methoxyethoxy-carbonylaminomethyl-, methanesulfonyl-N-methylamino-methyl-, 4,5-dihydro-oxazol-2-yl-, 2-oxo-pyrrolidin-1-yl-, 2-[(2-hydroxy-ethyl)-methyl-amino]-ethoxy-, 3-hydroxy-2-oxo-pyr
  • R 8 may be selected from:
  • R 30 and R 31 each independently is selected from hydrogen, methyl, ethyl, methoxyethyl and hydroxyethyl, and R 32 is hydrogen, methyl or ethyl.
  • R 8 may be selected from:
  • Y and Ar considered together may be selected from one of (A), (B), (C), or (D):
  • Y and Ar considered together may be selected from one of (A) and (B);
  • Ar is 2,3-dihydro-1H-isoindol-5-yl optionally substituted at the 2-position with methyl or 2-methoxyethyl.
  • Ar is 1H-indol-3-yl.
  • Y is heterocyclylene such as piperazin-1,4-di-yl or piperidin-1-3-di-yl.
  • Ar is pyridin 2-yl optionally substituted at the 4-position or 6-position with hydroxyalkoxy, optionally substituted pyrrolodinyl, alkylaminoalkyl, alkylsulfonylaminoalkyl, haloalkylaminoalkyl, alkoxyalkylaminoalkyl, hydroxyalkylaminoalkyl, aminoalkoxy, aminoalkyl, ureidylalkyl, carbamylalkyl, acetamidinyl, formamidinyl, optionally substituted imidazolinyl, optionally substituted pyrrolodinylmethyl, optionally substituted imidazolinylmethl, alkoxyalkylaminocarbonyl, hydroxyalkylaminocarbonyl, aminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, or heterocyclylalkylamino.
  • preferred compounds are those compounds having the Formula (Ib),
  • R 7 is selected from pyrrolidinyl, pyrrolinyl, imidazolinyl, —NR 12 R 14 , —NR 12 C( ⁇ NR 13 )R 14 , —N ⁇ C(R 15 )(R 16 ), —OR 17 , and C 1-4 alkyl optionally substituted with pyrrolidinyl, pyrrolinyl, imidazolinyl, —NR 12a R 14a , and/or —OR 17a , wherein said pyrrolidinyl, pyrrolinyl and imidazolinyl groups in turn optionally may be substituted with one to three of lower alkyl, halogen, cyano, and/or hydroxy(C 1-4 )alkyl; R 12 , R 12a , R 13 , R 14 , R 14a R 17 , and R 17a are independently selected from hydrogen
  • Y is methylene
  • R and R′ are methyl
  • R 5 is methoxy or methyl
  • R 7 and R 8 is hydrogen, or methoxy, and the other is selected from methyl-(3,3,3-trifluoro-propyl)-amino-methyl-, 2-hydroxy-3-methoxy-propoxy-, methoxy-, 3-hydroxy-2-hydroxymethyl-propoxy-, 1-(dimethylamino-carbonyl-methylamino)-ethyl-, 1-[(methoxycarbonyl)-methylamino]-ethyl-, 3-hydroxy-2-hydroxymethyl-propoxy-, 2,3-dihydroxypropoxy-, (S)-4-methoxy-2-oxo-pyrrolidin-1-yl-, 2-methoxyethoxy-carbonylaminomethyl-, methanesulfonyl-N-methylamino-methyl-, 4,5-dihydro-oxazol-2-yl-, 2-oxo-pyrrolidin-1-yl-, 2-[(2-hydroxy-ethyl)-methyl-amino]-,
  • R 10 is hydrogen or methyl.
  • R 5 is selected from methyl, methoxy, cyano and fluoro
  • R 7 is selected from one of:
  • R 30 , R 31 , and R 32 are independently selected from hydrogen and methyl.
  • combinations of the preferred groups described herein form other preferred embodiments.
  • a variety of preferred compounds are embodied within the present invention.
  • another group of preferred compounds selected from a combination of preferred groups recited above, are those compounds having the formula (Ic), as immediately defined above, wherein R 5 is fluoro, cyano, methyl, or methoxy, and R 10 is methyl.
  • R 5 is fluoro, cyano, methyl, or methoxy
  • R 10 is methyl.
  • a 5-position substituent on the quinazolinone core produces an unexpected and/or surprising advantage with regard to the compounds' effectiveness as selective antagonists of the alpha-1A and alpha-1B adrenoceptors.
  • the 5-position substituent advantageously affects the metabolic pathway for the claimed quinazolinone compounds and increases their bioavailability, thus enhancing their pharmacological effects.
  • Alpha-1 adrenoceptors mediate the contractile state of smooth muscle tissue and are present in the human prostate, bladder neck and urethra. Alpha-1 adrenoceptor stimulation also produces contraction of urethral and bladder neck smooth muscle, leading to increased resistance in urinary outflow. Thus, alpha-1 adrenoceptor antagonists may be useful in treating disorders of the urinary tract, as previously defined.
  • Alpha-1B adrenoceptors are present in the liver, heart and cerebral cortex and are believed to be involved in mediating vascular contractile and blood pressure responses. Alpha-1B adrenoceptors are also present in areas of the spinal cord which receive input from sympathetic neurons originating in the pontine micturition center and are presumed to be involved in the regulation of bladder function. Additionally, alpha-1B adrenoceptor antagonists are useful as analgesic/antihyperalgesic therapies for treating pain, including symptoms of acute pain, inflammatory pain, neuropathic pain (including thermal and mechanical hyperalgesia as well as thermal and mechanical allodynia), complex regional pain syndromes (including reflex sympathetic dystrophy, causalgia and sympathetically maintained pain and the like).
  • the compounds of this invention are useful for treating disorders and symptoms which can be ameliorated by blockade of alpha 1A/B adrenoceptors, such as reduction or alleviation of urinary tract disorders, for example, pelvic hypersensitivity (including interstitial cystitis, prostatitis, pelvic pain syndrome, infectious cystitis, prostatodynia, and the like), overactive bladder, urinary frequency, nocturia, urinary urgency, detrusor hyperreflexia, outlet obstruction, BPH, prostatitis, urge incontinence, urethritis, idiophatic bladder hypersensitivity, sexual dysfunction, and the like.
  • pelvic hypersensitivity including interstitial cystitis, prostatitis, pelvic pain syndrome, infectious cystitis, prostatodynia, and the like
  • overactive bladder urinary frequency, nocturia, urinary urgency, detrusor hyperreflexia, outlet obstruction, BPH, prostatitis, urge incontinence, urethritis, idiophatic bladder hypersensitivity
  • the compounds of this invention are useful for treating disorders and symptoms which can be ameliorated by blockade of alpha-1A/B adrenoceptors, such as reduction or alleviation of pain disorders, for example inflammatory pain, neuropathic pain, cancer pain, acute pain, chronic pain or complex regional pain syndromes.
  • the compounds of this invention are useful for treating disorders and symptoms which can be ameliorated by blockade of both alpha-1A and alpha-1B adrenoceptors with diminished blockade of alpha-1D adrenoceptors, such as reduction or alleviation of both outlet obstruction, such as benign prostatic hypertrophy, and irritative symptoms associated with it, such as pain.
  • the compounds of this invention are useful for the improvement of sexual dysfunction including male erectile dysfunction (MED) and female sexual dysfunction (FSD).
  • MED male erectile dysfunction
  • FSD female sexual dysfunction
  • the present invention includes pharmaceutical compositions comprising at least one compound of the present invention, or an individual isomer, racemic or non-racemic mixture of isomers or a pharmaceutically acceptable salt or solvate thereof, together with at least one pharmaceutically acceptable carrier, and optionally other therapeutic and/or prophylactic ingredients.
  • the compounds of the present invention will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. Suitable dosage ranges are typically 1–500 mg daily, preferably 1–100 mg daily, and most preferably 1–30 mg daily, depending upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound used, the route and form of administration, the indication towards which the administration is directed, and the preferences and experience of the medical practitioner involved.
  • One of ordinary skill in the art of treating such diseases will be able, without undue experimentation and in reliance upon personal knowledge and the disclosure of this Application, to ascertain a therapeutically effective amount of the compounds of the present invention for a given disease.
  • compounds of the present invention will be administered as pharmaceutical formulations including those suitable for oral (including buccal and sublingual), rectal, nasal, topical, vaginal, or parenteral (including intramuscular, intraarterial, intrathecal, subcutaneous and intravenous) administration or pulmonary in a form suitable for administration by inhalation or insufflation.
  • oral including buccal and sublingual
  • parenteral including intramuscular, intraarterial, intrathecal, subcutaneous and intravenous
  • administration or pulmonary in a form suitable for administration by inhalation or insufflation.
  • the preferred manner of administration is generally oral using a convenient daily dosage regimen which can be adjusted according to the degree of affliction.
  • a compound or compounds of the present invention, together with one or more conventional adjuvants, carriers, or diluents, may be placed into the form of pharmaceutical compositions and unit dosages.
  • the pharmaceutical compositions and unit dosage forms may be comprised of conventional ingredients in conventional proportions, with or without additional active compounds or principles, and the unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
  • compositions may be employed as solids, such as tablets or filled capsules, semisolids, powders, sustained release formulations, or liquids such as solutions, suspensions, emulsions, elixirs, or filled capsules for oral use; or in the form of suppositories for rectal or vaginal administration; or in the form of sterile injectable solutions for parenteral use.
  • Formulations containing about one (1) to about 20 milligram of active ingredient or, more broadly, about 0.01 to about one hundred (100) milligrams, per tablet, are accordingly suitable representative unit dosage forms.
  • the compounds of the present invention may be formulated in a wide variety of oral administration dosage forms.
  • the pharmaceutical compositions and dosage forms may comprise a compound or compounds of the present invention or pharmaceutically acceptable salts thereof as the active component.
  • the pharmaceutically acceptable carriers may be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier may be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the carrier In powders, the carrier generally is a finely divided solid which is a mixture with the finely divided active component.
  • the active component In tablets, the active component generally is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain from about one (1) to about seventy (70) percent of the active compound.
  • Suitable carriers include but are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
  • the term “preparation” is intended to include the formulation of the active compound with encapsulating material as carrier, providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is in association with it.
  • cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges may be as solid forms suitable for oral administration.
  • liquid form preparations including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions, or solid form preparations which are intended to be converted shortly before use to liquid form preparations.
  • Emulsions may be prepared in solutions, for example, in aqueous propylene glycol solutions or may contain emulsifying agents, for example, such as lecithin, sorbitan monooleate, or acacia.
  • Aqueous solutions can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing, and thickening agents.
  • Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents.
  • Solid form preparations include solutions, suspensions, and emulsions, and may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
  • the compounds of the present invention may be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative.
  • the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol.
  • oily or nonaqueous carriers, diluents, solvents or vehicles examples include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and may contain formulatory agents such as preserving, wetting, emulsifying or suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water.
  • the compounds of the present invention may be formulated for topical administration to the epidermis as ointments, creams or lotions, or as a transdermal patch.
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and will in general also containing one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents.
  • Formulations suitable for topical administration in the mouth include lozenges comprising active agents in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • the compounds of the present invention may be formulated for administration as suppositories.
  • a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted and the active component is dispersed homogeneously, for example, by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and to solidify.
  • the compounds of the present invention may be formulated for vaginal administration.
  • Pessaries, tampons, creams, gels, pastes, foams or sprays may contain in addition to the active ingredient, such carriers as are known in the art to be appropriate.
  • the compounds of the present invention may be formulated for nasal administration.
  • the solutions or suspensions are applied directly to the nasal cavity by conventional means, for example, with a dropper, pipette or spray.
  • the formulations may be provided in a single or multidose form.
  • dosing may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension.
  • this may be achieved for example by means of a metering atomizing spray pump.
  • the compounds of the present invention may be formulated for aerosol administration, particularly to the respiratory tract and including intranasal administration.
  • the compound will generally have a small particle size for example on the order of five (5) microns or less. Such a particle size may be obtained by means known in the art, for example by micronization.
  • the active ingredient is provided in a pressurized pack with a suitable propellant such as a chlorofluorocarbon (CFC), for example, dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, or carbon dioxide or other suitable gas.
  • CFC chlorofluorocarbon
  • the aerosol may conveniently also contain a surfactant such as lecithin.
  • the dose of drug may be controlled by a metered valve.
  • the active ingredients may be provided in a form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, and starch derivatives such as hydroxypropylmethyl cellulose, and polyvinylpyrrolidine (PVP).
  • a suitable powder base such as lactose, starch, and starch derivatives such as hydroxypropylmethyl cellulose, and polyvinylpyrrolidine (PVP).
  • the powder carrier will form a gel in the nasal cavity.
  • the powder composition may be presented in unit dose form for example in capsules or cartridges of e.g., gelatin or blister packs from which the powder may be administered by means of an inhaler.
  • formulations can be prepared with enteric coatings adapted for sustained or controlled release administration of the active ingredient.
  • the compounds of the present invention can be formulated in transdermal or subcutaneous drug delivery devices. These delivery systems are advantageous when sustained release of the compound is necessary and when patient compliance with a treatment regimen is crucial.
  • Compounds in transdermal delivery systems are frequently attached to an skin-adhesive solid support.
  • the compound of interest can also be combined with a penetration enhancer, e.g., Azone (1-dodecylazacycloheptan-2-one).
  • Sustained release delivery systems are inserted subcutaneously into to the subdermal layer by surgery or injection.
  • the subdermal implants encapsulate the compound in a lipid soluble membrane, e.g., silicone rubber, or a biodegradable polymer, e.g., polylactic acid.
  • the pharmaceutical preparations are preferably in unit dosage forms.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • the starting materials and reagents used in preparing these compounds generally are either available from commercial suppliers, such as Aldrich Chemical Co., or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser 's Reagents for Organic Synthesis ; Wiley & Sons: New York, 1991, Volumes 1–15 ; Rodd's Chemistry of Carbon Compounds , Elsevier Science Publishers, 1989, Volumes 1–5 and Supplementals; and Organic Reactions , Wiley & Sons: New York, 1991, Volumes 1–40.
  • the following synthetic reaction schemes are merely illustrative of some methods by which the compounds of the present invention may be synthesized, and various modifications to these synthetic reaction schemes may be made and will be suggested to one skilled in the art having referred to the disclosure contained in this application.
  • the starting materials and the intermediates of the synthetic reaction schemes may be isolated and purified if desired using conventional techniques including but not limited to filtration, distillation, crystallization, chromatography, and the like. Such materials may be characterized using conventional means, including physical constants and spectral data.
  • the reactions described herein preferably take place at atmospheric pressure over a temperature range from about ⁇ 78° C. to about 150° C., more preferably from about 0° C. to reflux, and most preferably and conveniently at about room (or ambient) temperature, e.g., about 20° C.
  • Compounds of formula (Ia) can be prepared by coupling 2-chloro-quinazoline-4-one compounds (1) with amine compounds (2), in a solvent such as EtOH, with or without additives such as diisopropylethylamine.
  • Quinazolin-4-ones can be prepared as described in Cronin et al., J. Med. Chem , Vol. 11 (1968), at pp. 130–136, and WO 02/053558 A1, which are incorporated herein by reference.
  • 2-chloro-quinazoline-4-one compounds (1) can be prepared as described below using the method described in Scheme 3.
  • 2-Chloro-quinazolin-4-one compounds (1) can be converted to compounds of formula (Ie) by combining amines such as (3)(or a suitable salt of such amines, e.g. HCl salt thereof) with compounds (1) in a solvent, such as isopropanol, and heating the reaction mixture in the presence or absence of an additive like diisopropylethylamine.
  • Compounds (Ie) can be isolated by cooling and filtering the reaction mixture. In some cases, the recovery of product can be increased by adding an anti-solvent (e.g. water) prior to performing the filtration.
  • an anti-solvent e.g. water
  • Compounds of formula (1f) can be prepared by combining compounds (Ie), a heterogenous catalyst on an inert support (e.g. palladium on carbon), an organic solvent (e.g. ethanol), water, and base (e.g. NaOH). Then, to this reaction mixture, hydrogen is introduced either directly or indirectly (e.g., via transfer hydrogenation using formate salts, hydrazine, etc.), and the nitro group is reduced to an amino group. The catalyst and support are removed, and the reaction mixture is neutralized by addition of acid (e.g. acetic, trifluoroacetic, hydrochloric acid, etc). The precipitated compound of formula (1f) is then collected via filtration.
  • an inert support e.g. palladium on carbon
  • an organic solvent e.g. ethanol
  • base e.g. NaOH
  • Compounds of formula (1g) can be prepared by combining compounds of formula (1f) in an organic solvent (methylene chloride, acetonitrile, etc) and a solution of iminium salt (4) (prepared by activation of the appropriate acetamide or formamide with phosphorous oxychloride or trifluoromethanesulfonic anhydride as described by Fabio et al, J. Med. Chem , Vol.
  • an organic solvent methylene chloride, acetonitrile, etc
  • iminium salt (4) prepared by activation of the appropriate acetamide or formamide with phosphorous oxychloride or trifluoromethanesulfonic anhydride as described by Fabio et al, J. Med. Chem , Vol.
  • Quinazolin-4-ones (1) can be prepared as described in Cronin et al. or WO 02/053558 A1, cited above, or using the method described in Scheme 3.
  • Scheme 3 illustrates an alternate method for making 2-chloro-quinazolin-4-one compounds (1), used as starting material in Schemes 1 and 2.
  • Dione intermediate (5) is converted to dichloroquinazoline (6) by combining (5) with a chlorinating and dehydrating agent (e.g., phosphorous oxychloride) in an organic solvent (e.g. acetonitrile) and heating the reaction mixture.
  • a chlorinating and dehydrating agent e.g., phosphorous oxychloride
  • organic solvent e.g. acetonitrile
  • the dichloroquinazoline (6) is isolated by quenching the reaction mixture into water and filtering the precipitated product, or by quenching the reaction mixture into a mixture of water and a water-immiscible solvent (e.g. methylene chloride), and extracting the product into the organic solvent.
  • the solvent is evaporated to provide compound (6).
  • Compound (6) is then combined with a base (e.g., KOH, NaOH) in a mixture of water and a solvent like THF.
  • a base e.g., KOH, NaOH
  • the organic solvent is partially removed by distillation, an acid (e.g. HOAc) is added, and the compound (1) is collected via filtration.
  • Dione intermediates (5) are commercially available or can be readily prepared by one skilled in the field, e.g., as described in Mizuno et al., Heteroatom Chemistry , Vol. 11 (6) (2000), at pp. 428–433; Mizuno et al., Tetrahedron Letters , Vol. 41 (7) (2000), at pp. 1051–51; U.S. Pat. No. 6,376,667-B1; U.S. Pat. No. 6,048,864; WO 97/23462; EP Pat. 775697-A1; and so forth.
  • dione intermediates (5) may be prepared as described in Scheme 4.
  • Scheme 4 illustrates an alternative method for making of diones (5), used in Scheme 3 to prepare 2-chloro-quinazolin-4-one compounds (1).
  • Nitro-acids (8) are commercially available, or can be readily prepared by one skilled in the field from carboxylic acids (7) using several methods, including that of Kowalczyk et al., Organic Process Research and Development , Vol. 1 (1997), at pp. 355–358. Carboxylic acids (7) are commercially available.
  • Nitro acids (8) are dissolved in water by addition of base (e.g., NaOH, KOH, LiOH). Typically, the amount of base used to dissolve the acids is in the range of a 1.3 to 1.5 molar equivalent, e.g., at a pH ⁇ 12.
  • a heterogenous catalyst on an inert support is added (e.g., palladium on carbon), and the reaction mixture is exposed to a hydrogen atmosphere either directly (hydrogen gas) or indirectly (via transfer hydrogenation technique using, e.g., formate salts, hydrazine, etc., as the hydrogen source). The nitro-group is thereby converted to an amino group to provide compounds (9).
  • Compounds (9) can be converted to urea (10) by addition of a cyanate salt (e.g., KOCN, NaOCN) and an acid (e.g., HCl, HOAc).
  • a cyanate salt e.g., KOCN, NaOCN
  • an acid e.g., HCl, HOAc
  • the pH is preferably maintained in the range of 6.0 to 8.0, more preferably between 6.8 and 8.0.
  • the urea formation step may slow down, and when the pH is between 5.6 and 6.0, an undesirable side reaction may occur. Degradation occurs at lower pH, e.g., at pH of ⁇ 3.9.
  • the urea (10) is then cyclized to a dione derivative (5) by adding a base (e.g., NaOH, KOH), wherein the pH is typically maintained at ⁇ 12, and heating the reaction mixture.
  • a base e.g., NaOH, KOH
  • the results of this cyclization step may be improved as the pH is increased.
  • the dione (5) is precipitated by adding an acid (e.g., HCl, HOAc) to the reaction mixture, to achieve a pH of about less than 8.2, more preferably in the range of 6.5 to 7.5, and the dione (5) may be isolated such as by filtration.
  • Other acids also may be used, e.g., any acid that will generate HOCN in-situ from the cyanate salt and the acid.
  • Benzylamine (1) was prepared following the procedure of Sznaidman et al., Bioorg. Med. Chem. Lett., 6(5) (1996), at pp. 565–568.
  • the carbamate (2) from Step 2 (7.6 g, 27.5 mmol) was dissolved in 70 mL THF and added over a period of 30 min. to a stirred slurry of 3 g (75 mmol) of LAH in 300 mL of diethyl ether. The mixture was stirred at reflux for 8 h and allowed to stand at ambient temperature for 16 h. The reaction was quenched while stirring by sequential addition of 1—water; 2—15% NaOH and 3—water until all solids appeared to be white. The solids were removed by filtration and washed once with THF. The filtrates were combined, concentrated under reduced pressure, and the remaining oil was distilled to yield 4.1 g (78%) of the N-methylbenzylamine (3). Bp 140° C./1 mm.
  • the bis HCl salt was obtained when the free base in hot EtOH was treated with an excess of 10% HCl in EtOH, and was crystallized by addition of diethyl ether. Mp 220–223° C. Anal. (C 22 H 26 N 4 O 3 .2HCl), Calcd.: C, 56.54; H, 6.04; N, 11.99. Found: C, 56.20; H, 6.01; N, 11.95.
  • Benzylamine (1) was prepared following the procedure of Harper et al., Journal of Medicinal Chemistry , Vol. 7(6) (1964), at pp. 729–32.
  • Example B-1 in vacuo furnishing 3.7 g (90%) of Example B-1 as an off-white solid. Mp 268–269.5° C.; Anal. (C 19 H 22 N 4 O 3 ) Calcd.: C, 64.39; H, 6.26; N, 15.81. Found: C, 64.05; H, 6.25; N, 15.49.
  • Step 1 3-[2-(tert-Butyl-dimethyl-silanyloxy)-ethoxy]-benzaldehyde.
  • Step 2 ⁇ 3-[2-(tert-Butyl-dimethyl-silanyloxy)-ethoxy]-benzylidene ⁇ -methyl-amine.
  • Step 3 ⁇ 3-[2-(tert-Butyl-dimethyl-silanyloxy)-ethoxy]-benzyl ⁇ -methyl-amine.
  • Step 4 2-( ⁇ 3-[2-(tert-Butyl-dimethyl-silanyloxy)-ethoxy]-benzyl ⁇ -methyl-amino)-5,6,7-trimethoxy-1H-quinazolin-4-one.
  • Step 5 2- ⁇ [3-(2-Hydroxy-ethoxy)-benzyl]-methyl-amino ⁇ -5,6,7-trimethoxy-1H-quinazolin-4-one.
  • Step 1 3-Methylsulfanylmethoxy-benzaldehyde.
  • Step 2 Methyl-(3-methylsulfanylmethoxy-benzylidene)-amine.
  • 3-Methylsulfanylmethoxy-benzaldehyde from step 1 (3.309 g, 18.16 mmol) was dissolved in EtOH (9 mL). MeNH 2 (2.55 mL, 40% in H 2 O) was added and the mixture was heated to 40° C. for 30 min. Upon cooling, the mixture was concentrated in vacuo. The aqueous residue was diluted with isopropanol and then concentrated in vacuo. This was repeated twice more giving 3.55 g (quant) of a pale yellow oil.
  • Step 3 Methyl-(3-methylsulfanylmethoxy-benzyl)-amine.
  • Step 4 (3-Methanesulfinylmethoxy-benzyl)-methyl-amine.
  • Step 5 2-[(3-Methanesulfinylmethoxy-benzyl)-methyl-amino]-6,7-dimethoxy-5-methyl-1 H-quinazolin-4-one.
  • Example B-1 The aniline of Example B-1 (600 mg, 1.7 mmol), the dimethylacetal of DMF (330 mg, 2.23 mmol), and DMF (2 mL) was kept at 100° C. for 35 min and then stored at ambient temperature for 16 h. The precipitated product was collected and washed with diethyl ether affording 340 mg of product. This material was further purified by chromatography (EM Science silica gel 60; 3% MeOH in DCM containing 0.5% of ammonium hydroxide) to yield 250 mg (35%) of the above compound as a white solid. Mp 174.4–174.8° C.; ms 424 (M+H).
  • the HCl salt of the above compound was prepared mixing 600 mg (1.4 mmol) of the free base with 8 mL hot EtOH, and then adding to this solution 2.7 mL of a 1.4 M solution of HCl in EtOH (3.7 mmol).
  • the HCl salt was crystallized by addition of diethyl ether.
  • the collected product was dried at 80° C. in vacuo to furnish 620 mg. Mp 170.6–172.5° C.; Anal. (C 23 H 29 N 5 O 3 .2HCl.0.5H 2 O) Calcd.: C, 54.65; H, 6.38; N, 13.86. Found: C, 54.40; H, 6.14; N, 13.81.
  • Trifluoroacetic acid (375 ⁇ L, 4.87 mmol) was added via syringe to a stirred solution of (3) from Step 2 (189 mg, 0.62 mmol) at 0° C. After 3 hours, the solution was concentrated under reduced pressure, then pumped under vacuum for 1 hour. The crude residue was dissolved in EtOH (2 mL), and added to a sealed tube containing 2-chloro-5,6,7-trimethoxy-1H-quinazolin-4-one (132 mg, 0.49 mmol), diisopropylethylamine (425 ⁇ L, 2.44 mmol), and EtOH (3 mL). The suspension was heated at 110° C. for 2 hours, then cooled to room temperature and stirred overnight.
  • Diisopropylethylamine (0.82 mL, 4.71 mmol) was added to the mixture of 2-chloro-6,7-dimethoxy-5-methyl-quinazolin-4-one (1.0 g, 3.92 mmol) and N-methyl-(3-cyano-benzyl)-amine (0.68 g, 4.71 mmol) in EtOH (50 mL). It was heated at 120° C. for 1.5 h in the sealed tube.
  • Example H-2 A few drops of carbondisulfide was added to a solution of the arylnitrile of Example B-2, above (0.08 g, 0.219 mol) in 1 mL of N-methylethylendiamine. The mixture was allowed to stir at 120° C. for 2 h. The excess amine was evaporated under reduced pressure and purified by flash column chromatography to provide the above Example H-2.
  • Step 1 4-(3-Methylcarbamoylphenyl)piperidine-1-methylcarboxamide.
  • Step 2 Methyl-[3-(1-methylpiperidin-4-yl)benzyl]amine.
  • Step 1 6,7,8-Trimethoxy-1,1-dioxo-1,4-dihydro-2H-1lambda*6*-benzo[1,2,4]thiadiazin-3-one
  • the resulting mixture was cooled to rt and poured into ice water.
  • the aqueous layer was removed from the resulting black gum, which contained some of the desired material, as well as starting material and side products.
  • the aqueous layer was shaken with EtOAc and the layers separated.
  • the organic layer was evaporated in vacuo and the residue crystallized from a small amount of EtOAc to yield 6,7,8-trimethoxy benzothiadiazine-3-one-1,1-dioxide.
  • the potency and selectivity of the inventive compounds as ⁇ 1A/B antagonists was determined with CHO-K1 cells expressing adrenoceptor subtype ⁇ 1A-215, ⁇ 1B or ⁇ 1D by measuring cAMP accumulation using AlphaScreen.
  • Cell preparation was accomplished by culturing CHO- ⁇ 1 cloned cells in Ham's F12 nutrient media supplemented with 10% FBS and G418 (25 mg/mL), harvested at 80% confluence, washed with warmed PBS ⁇ 2, and detached with versene for 5 min. at 37° C. The cultured cells were then resuspended in 40 mL of stimulation buffer (HBSS with 5 mM hepes, 0.1% BSA) and centrifuged at 500–100 rpm for 5 min. The obtained pellet was resuspended in stimulation buffer (with 0.5M IBMX), and the cells were counted. Cells were diluted to the desired number of cells/mL ( ⁇ 1A at 3 ⁇ 10 6 /mL, ⁇ 1B 15 ⁇ 10 6 /mL, and ⁇ 1D 20 ⁇ 10 6 /mL).
  • stimulation buffer with 0.5M IBMX
  • the compounds being tested were diluted in stimulation buffer (with 0.5M IBMX), from 10 ⁇ 5 to 10 ⁇ 11 (final) dilution, 11 points.
  • 5 ⁇ l of each compound was dispensed to 96 well 1 ⁇ 2 area plates in triplicate.
  • 5 ⁇ l of stimulation buffer was dispensed to a norepinephrine (NE) plate.
  • 10 ⁇ l of cells were added with anti-cAMP Acceptor beads in stimulation buffer to each plate and incubated for 15 min. at RT (in dark or covered with black plate).
  • NE was added to the antagonist plates, at 1 ⁇ M for ⁇ 1A and 1B and at 100 nM for ⁇ 1D, and then 5 ⁇ l serial dilution of NE was added to NE plate. Plates were incubated for 30 min. at RT (in dark or covered with black plate) and 10 ⁇ l Donor beads+biotin-cAMP in lysis buffer (5 mM Hepes, 0.54% Tween-20, 0.1% BSA) was added. Plates were incubated for 3 h. at RT with gentle shaking (in dark or covered with black plate). Plates were read on an AlphaScreen Fusion analyzer, using reagent pursuant to AlphaSreen cAMP detection kit (PerkinElmer Cat#6760600).
  • pEC 50 being the negative logarithm of EC 50 , i.e., the molar concentration of an agonist which produces 50% of the maximum possible response for that agonist
  • pKb is the negative logarithm of Kb
  • Alpha1A, alpha1B, and alpha1D adrenoceptor transfected CHO-K1 cells prepared using the methods described by Chang et al., FEBS Lett. 1998, 422:279–283, were grown to confluence in T-162 tissue culture flasks in Ham's F-12 culture medium supplemented with 10% fetal bovine serum, geneticin (150 ⁇ g/mL) and streptomycin/penicillin (30 ⁇ g/mL/30 ⁇ g/mL) at 37° C. in 7% CO 2 . Cells were harvested by incubating with phosphate-buffered saline (PBS) containing 30 ⁇ M EDTA for 5–10 min at 37° C.
  • PBS phosphate-buffered saline
  • Cells were pelleted by centrifuging at 500 ⁇ g for 5 min, and the pelleted cells were homogenized (Polytron homogenizer) in 10 vols (w/v) of 50 mM Tris, 1 mM EDTA, (homogenisation buffer, pH 7.4 at 4° C.). The homogenate was centrifuged at 45,000 ⁇ g for 20 min. The pellet was resuspended in the homogenizing buffer and rehomogenized. The resulting homogenate was centrifuged at 45,000 ⁇ g for 20 min. The pellet was resuspended in 50 mM Tris buffer (pH 7.4 at 4° C.), aliquoted, frozen, and stored at ⁇ 80° C. for further use.
  • the membranes were thawed at room temperature and diluted in assay buffer (50 mM Tris buffer at pH 4) at 37° C. and homogenized using the Polytron tissue disrupter. The membranes were incubated with the radioligand ([ 3 H]prazosin, NEN, 0.1–0.5 nM) and test compound at 37° C. for 30 min. The membranes were then filtered over polyethyleneimine-treated GF/B unifilter plates using a Packard Filtermate Harvester and washed with ice-cold 50 mM Tris-HCl, 1 mM EDTA buffer (3 ⁇ 3 sec. washes). Scintillation cocktail was added to the filter plates and bound radioligand determined by liquid scintillation spectrophotometry.
  • radioligand [ 3 H]prazosin, NEN, 0.1–0.5 nM
  • the following describes an in vivo assay for measuring the relative effect of test compounds on hypogastric nerve stimulation-induced increases in intraurethral pressure and phenylephrine-induced increases in diastolic blood pressure in anesthetized dog.
  • phenobarbital sodium 36 mg/kg, i.v.
  • An endotracheal tube was inserted and thereafter the lungs were mechanically ventilated with room air.
  • the right femoral vein was isolated and cannulated with two polyethylene cannulae, one for the administration of a continuous infusion of phenobarbital sodium (5 to 10 mg/kg/hr) and the other for bolus administration of test substances.
  • the right femoral artery was isolated and cannulated to the abdominal aorta with a fluid filled polyethylene cannula connected to an external pressure transducer for monitoring diastolic aortic pressure (DAP).
  • DAP diastolic aortic pressure
  • the bladder was exposed via a ventral midline abdominal incision and emptied of urine through a 22 gauge needle.
  • the bladder was cannulated through a stab incision with a water filled balloon catheter connected to an external pressure transducer for monitoring prostatic intraurethral pressure (IUP).
  • IUP prostatic intraurethral pressure
  • the right hypogastric nerve (HGN) was carefully isolated and attached to a Dastre's electrode for nerve stimulation.
  • the preparation was allowed to stabilize for at least 20–30 minutes and must have had a stable basal IUP for not less than 15 minutes prior to commencement of the assay protocol.
  • the HGN was stimulated (20–50V, 10 Hz, 10 msec pulse train for 10 sec) to induce a measurable increase in IUP and then phenylephrine (PE) was administered by bolus injection (6 ⁇ g/kg, i.v.) to induce a measurable increase in DAP.
  • PE phenylephrine
  • the HGN stimulation and PE bolus injection were repeated every 5 minutes until three consecutive reproducible increases in IUP and DAP were achieved.
  • Test compound was administered and 10 minutes later the HGN stimulation and PE bolus injection were repeated. Test compound was administered approximately every 20 minutes, increasing the dose until maximal or near maximal inhibition of the increases in IUP and DAP is attained.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
US10/884,768 2003-07-02 2004-07-02 Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists Expired - Fee Related US7244738B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/884,768 US7244738B2 (en) 2003-07-02 2004-07-02 Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists
US11/821,493 US20070265446A1 (en) 2003-07-02 2007-06-22 Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48457003P 2003-07-02 2003-07-02
US10/884,768 US7244738B2 (en) 2003-07-02 2004-07-02 Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/821,493 Continuation US20070265446A1 (en) 2003-07-02 2007-06-22 Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists

Publications (2)

Publication Number Publication Date
US20050038016A1 US20050038016A1 (en) 2005-02-17
US7244738B2 true US7244738B2 (en) 2007-07-17

Family

ID=34062056

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/884,768 Expired - Fee Related US7244738B2 (en) 2003-07-02 2004-07-02 Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists
US11/821,493 Abandoned US20070265446A1 (en) 2003-07-02 2007-06-22 Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/821,493 Abandoned US20070265446A1 (en) 2003-07-02 2007-06-22 Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists

Country Status (13)

Country Link
US (2) US7244738B2 (ru)
EP (1) EP1644369A2 (ru)
JP (1) JP2009513502A (ru)
KR (1) KR100802856B1 (ru)
CN (1) CN1845924A (ru)
AR (1) AR045007A1 (ru)
AU (1) AU2004255581A1 (ru)
BR (1) BRPI0412285A (ru)
CA (1) CA2530312A1 (ru)
MX (1) MXPA05013905A (ru)
RU (1) RU2006102869A (ru)
TW (1) TW200519097A (ru)
WO (1) WO2005005395A2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070265446A1 (en) * 2003-07-02 2007-11-15 Connolly Terrence J Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1884262B (zh) * 2005-06-24 2014-06-25 中国人民解放军军事医学科学院毒物药物研究所 4-氨基哌啶类化合物及其医药用途
MX2009003673A (es) * 2006-10-04 2009-04-22 Pfizer Prod Inc Derivados de piridido[4,3-d]pirimidin-4(3h)-ona como antagonistas de los receptores de calcio.
WO2009026584A1 (en) * 2007-08-23 2009-02-26 Novelmed Therapeutics, Inc. Methods of treating inflammatory conditions with adrenergic antagonists
US20110195974A1 (en) * 2007-08-24 2011-08-11 Rekha Bansal Methods of treating inflammatory conditions with adrenergic antagonists
GB2453116B (en) * 2007-09-25 2010-03-17 Medical & Pharm Ind Tech & Dev Uses of 2-[piperidinyl]methy1-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one in providing an analgesic effect
EP2042179A1 (en) * 2007-09-26 2009-04-01 sanofi-aventis Novel therapeutic uses of adrenergic alpha-1 receptor antagonists
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
US8501997B2 (en) 2008-08-25 2013-08-06 Air Products And Chemicals, Inc. Curing agent for low temperature cure applications
US8512594B2 (en) * 2008-08-25 2013-08-20 Air Products And Chemicals, Inc. Curing agent of N,N′-dimethyl-meta-xylylenediamine and multifunctional amin(s)
MX2011003168A (es) * 2008-09-29 2011-05-19 Gilead Sciences Inc Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples.
CN103275017B (zh) * 2013-05-30 2015-07-01 温州大学 一种2-取代喹唑啉酮化合物及其合成方法和用途
KR102630720B1 (ko) * 2015-08-28 2024-01-29 세키스이 메디칼 가부시키가이샤 벤질 화합물
CN108358856B (zh) * 2018-01-08 2019-09-13 牡丹江医学院 一种防治消化性溃疡的药物以及其制备方法和用途
CN108358903B (zh) * 2018-04-24 2021-03-26 温州大学 2-取代杂环喹唑啉酮类化合物的合成方法
TW202311275A (zh) * 2021-08-05 2023-03-16 日商積水醫療股份有限公司 烷基矽烷氧取代苄基化合物之製造方法

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2258561A1 (de) 1971-12-02 1973-06-20 Byk Gulden Lomberg Chem Fab Basisch substituierte pyrimidon-(4)derivate, verfahren zu deren herstellung und sie enthaltende arzneimittel
US4442094A (en) 1980-12-23 1984-04-10 Merck & Co., Inc. (3-Aralkylamino-2-or-propoxy)heterocyclic compounds
US5084457A (en) 1990-07-23 1992-01-28 American Cyanamid Company Benzoylaminoquinazolinones
EP0498723A1 (fr) 1991-02-07 1992-08-12 Roussel Uclaf Dérivés bicycliques azotés, leur procédé de préparation, leur application à titre de médicament et les compositions pharmaceutiques les renfermant
WO1995012592A1 (de) 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue pyrazincarboxamidderivate, ihre herstellung und ihre verwendung in arzneimitteln
US5869665A (en) 1994-08-08 1999-02-09 Warner-Lambert Company Quinazolinone derivatives as cholecystokinin (CCK) ligands
WO1999042456A2 (en) 1998-02-18 1999-08-26 Neurosearch A/S Novel compounds and their use as positive ampa receptor modulators
WO1999048878A1 (en) 1998-03-24 1999-09-30 Novo Nordisk A/S Heterocyclic compounds regulating clotting
US6156758A (en) 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
WO2001010860A2 (en) 1999-08-05 2001-02-15 F. Hoffmann-La Roche Ag Quinazolinone and azaquinazolinone derivatives
WO2001070737A2 (en) 2000-03-20 2001-09-27 Sepracor, Inc. Therapeutic heterocyclic compounds for the treatment of asthma and allergy and use thereof
WO2001081340A2 (en) 2000-04-24 2001-11-01 Bristol-Myers Squibb Company Heterocycles that are inhibitors of impdh enzyme
WO2002024667A1 (en) 2000-09-20 2002-03-28 Merck Patent Gmbh 4-amino-quinazolines
US6376667B1 (en) 1997-11-26 2002-04-23 Osi Pharmaceuticals, Inc. Solid phase synthesis of heterocycles
WO2002048152A2 (en) 2000-12-12 2002-06-20 Neurogen Corporation Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
WO2002053558A1 (en) 2001-01-02 2002-07-11 F.Hoffman-La Roche Ag Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2530312A1 (en) * 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag Arylamine-substituted quinazolinone compounds

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2258561A1 (de) 1971-12-02 1973-06-20 Byk Gulden Lomberg Chem Fab Basisch substituierte pyrimidon-(4)derivate, verfahren zu deren herstellung und sie enthaltende arzneimittel
US4442094A (en) 1980-12-23 1984-04-10 Merck & Co., Inc. (3-Aralkylamino-2-or-propoxy)heterocyclic compounds
US5084457A (en) 1990-07-23 1992-01-28 American Cyanamid Company Benzoylaminoquinazolinones
EP0498723A1 (fr) 1991-02-07 1992-08-12 Roussel Uclaf Dérivés bicycliques azotés, leur procédé de préparation, leur application à titre de médicament et les compositions pharmaceutiques les renfermant
WO1995012592A1 (de) 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue pyrazincarboxamidderivate, ihre herstellung und ihre verwendung in arzneimitteln
US5869665A (en) 1994-08-08 1999-02-09 Warner-Lambert Company Quinazolinone derivatives as cholecystokinin (CCK) ligands
US6376667B1 (en) 1997-11-26 2002-04-23 Osi Pharmaceuticals, Inc. Solid phase synthesis of heterocycles
WO1999042456A2 (en) 1998-02-18 1999-08-26 Neurosearch A/S Novel compounds and their use as positive ampa receptor modulators
WO1999048878A1 (en) 1998-03-24 1999-09-30 Novo Nordisk A/S Heterocyclic compounds regulating clotting
WO2001010860A2 (en) 1999-08-05 2001-02-15 F. Hoffmann-La Roche Ag Quinazolinone and azaquinazolinone derivatives
US6156758A (en) 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
WO2001070737A2 (en) 2000-03-20 2001-09-27 Sepracor, Inc. Therapeutic heterocyclic compounds for the treatment of asthma and allergy and use thereof
WO2001081340A2 (en) 2000-04-24 2001-11-01 Bristol-Myers Squibb Company Heterocycles that are inhibitors of impdh enzyme
WO2002024667A1 (en) 2000-09-20 2002-03-28 Merck Patent Gmbh 4-amino-quinazolines
WO2002048152A2 (en) 2000-12-12 2002-06-20 Neurogen Corporation Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
WO2002053558A1 (en) 2001-01-02 2002-07-11 F.Hoffman-La Roche Ag Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ABSTRACT Database Beilstein XP002315228 Szabo, Vinkler, S., Acta Chim. Acad. Sci. Hung., (1958) pp. 201-207, vol. 17.
Andrus M.B., et al., "A Modified Synthesis of Iodoazidoaryl Prazosin", Journal Organic Chemistry (2002) pp. 8284-8286, vol. 67.
DeRuiter, et al., Design and Synthesis of 2-(Arylamino)-4(3H)-quinazolinones as Novel Inhibitors of Rat Lens Aldose Reductase, J. Med. Chemical, (1986), pp. 627-629, 29(5).
Hess, et al., "Antihypertensive 2-Amino-4(3H)-quinazolinones," J. Med. Chemical, (1968), pp. 130-136, 11(1).
Hess, H. et. al., "Antihypertensive 2-Amino-4(3H)-quinazolinones", J. Med. Chem., 1968, vol. 11, pp. 130-136. *
Klopman, et al., "An Artificial Intelligence Approach to the Study of the Structural Moieties Relevant to Drug-Receptor Interactions in Aldose Reductase Inhibitors," Mol. Pharmacol., (1988), pp. 852-862, 34(6).

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070265446A1 (en) * 2003-07-02 2007-11-15 Connolly Terrence J Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists

Also Published As

Publication number Publication date
JP2009513502A (ja) 2009-04-02
CN1845924A (zh) 2006-10-11
RU2006102869A (ru) 2007-08-10
CA2530312A1 (en) 2005-01-20
EP1644369A2 (en) 2006-04-12
AR045007A1 (es) 2005-10-12
KR100802856B1 (ko) 2008-02-12
WO2005005395A2 (en) 2005-01-20
TW200519097A (en) 2005-06-16
AU2004255581A1 (en) 2005-01-20
US20050038016A1 (en) 2005-02-17
WO2005005395A3 (en) 2005-05-06
KR20060031675A (ko) 2006-04-12
BRPI0412285A (pt) 2006-09-19
US20070265446A1 (en) 2007-11-15
MXPA05013905A (es) 2006-02-24

Similar Documents

Publication Publication Date Title
US20070265446A1 (en) Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists
EP1363899B1 (en) Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
US5859014A (en) Pyrimidinedione, pyrimidinetrione, triazinedione and tetrahydroquinazolinedione derivatives as α1 -adrenergic receptor antagonists
CA2178548A1 (en) Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydro-quinazolinedione derivatives as .alpha.1 adrenergic receptor antagonists
AU2001293788B2 (en) Quinazoline derivatives as alpha-1 adrenergic antagonists
EP1644343B1 (en) 5-substituted quinazolinone derivatives
AU2001293788A1 (en) Quinazoline derivatives as alpha-1 adrenergic antagonists
WO2000055143A1 (en) Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators
US7091200B2 (en) Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
US6376500B2 (en) Substituted 2-(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)-4(3H)-azaquinazolinones
US6355641B1 (en) Oxazolone derivatives and uses thereof
AU2002234586A1 (en) Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists

Legal Events

Date Code Title Description
AS Assignment

Owner name: ROCHE PALO ALTO LLC, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CONNOLLY, TERRENCE JOSEPH;KEITZ, PAUL FRANCIS;LEE, EUN KYUNG;AND OTHERS;REEL/FRAME:015151/0762;SIGNING DATES FROM 20040805 TO 20040811

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20110717